Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. (ONC) officer Wu Xiaobin, President and COO, reported selling 280 American Depositary Shares (ADS) of BeOne Medicines on 2026-08-25 at $380.00 per ADS in an open-market or private transaction. Each ADS represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 2025-11-07. After these transactions, Wu reported direct ownership of 1,270,084 Ordinary Shares and indirect ownership of 4,000 ADS held by his wife.
BeOne Medicines Ltd. (ONC) reported that it filed its 2026 Interim Report for the six months ended June 30, 2026 with the STAR Market of the Shanghai Stock Exchange, prepared under PRC GAAP, and furnished related U.S. GAAP information to U.S. investors. The company summarized key accounting differences between PRC GAAP and U.S. GAAP for share-based compensation, interim income tax calculation, lease presentation and the transfer of future royalty rights from a collaborative arrangement. It also disclosed a detailed U.S. GAAP breakdown of research and development expenses by key products and projects for the first half of 2026, showing total R&D expenses of US$1,153,504,000 versus US$1,006,783,000 a year earlier, including both external project spending and internal R&D costs.
BeOne Medicines Ltd. (ONC) received a notice on Form 144 indicating that officer Xiaobin Wu intends to sell up to 15,000 ADS of BeOne Medicines. The ADS were acquired upon the vesting of restricted stock units during the period from 06/05/2022 through 06/05/2023.
The proposed ADS sale is listed for execution through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with a noted date of 08/25/2026. The notice also reports that, during the past three months, Xiaobin Wu sold BeOne common shares in three transactions: 626 shares for $163,512.26 on 06/11/2026, 1,357 shares for $361,996.85 on 06/16/2026, and 1,292 shares for $356,926.89 on 06/23/2026.
BeOne Medicines Ltd. (ONC) has a notice of proposed sale under Rule 144 filed for securities beneficially owned by former director Corazon D. Sanders. The notice covers the planned sale of 2,075 ADS of BeOne Medicines Ltd., with an aggregate market value of $788,500.00, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or after 08/25/2026 on the NASDAQ market. The ADS were acquired by exercise of options under a registered plan for cash. In the preceding three months, Sanders sold 945 shares of common stock of BeOne Medicines Ltd. on 06/15/2026 for aggregate proceeds of $250,893.81.
BeOne Medicines Ltd. executive Lee Chan Henry, SVP and General Counsel, reported multiple option exercises and ADS trades on August 11, 2026. He exercised three option grants covering a total of 34,658 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per Ordinary Share. In related non-derivative transactions, he acquired blocks of 812, 1,058, and 796 American Depositary Shares (each ADS representing 13 Ordinary Shares), and sold 2,666 ADS at $360.00 per ADS pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. Following these transactions, he directly held 325,312 Ordinary Shares.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported open-market sales of a total of 240,810 American Depositary Shares (ADS) of the company over August 10–12, 2026, in 24 separate transactions at per-share prices generally between $350 and $367. Each ADS represents 13 Ordinary Shares. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Oyler on March 10, 2026. A direct holding line shows 1,330,988 Ordinary Shares held, and additional Ordinary Shares are held indirectly through various trusts and an IRA, some of which Oyler disclaims beneficial ownership of.
Chan Lee has filed to sell shares of BeOne Medicines under Rule 144. The planned transaction covers 718,718 American Depositary Shares (ADS), acquired in 2002, to be sold through Morgan Stanley Smith Barney LLC – Executive Financial Services on the NASDAQ, with a listed event date of 08/11/2026. The filing also notes that the ADS to be sold relate to the exercise of stock options for cash.
Over the prior three months, Lee reported multiple open-market sales, including 1,044 common shares for $337,932.36 on 07/30/2026 and several ADS transactions such as 1,669 ADS for $542,425.00 on 07/22/2026, 664 ADS for $200,833.44 on 07/08/2026, and additional ADS sales in June and May 2026, some under a Rule 10b5-1 trading plan.
The filing by insiders of ONC details planned and recent sales of equity under Rule 144. It lists 240,810 ADS to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $83,866,898.70, for trading on NASDAQ on or after August 10, 2026. The securities to be sold include ADS obtained from previously exercised stock options and ADS from founders shares. The filing also reports multiple recent 10b5-1 sales of ADS and common shares by John V. Oyler and the Pan-Oyler Foundation over June and July 2026, providing dates, share amounts, and dollar values for each transaction.
BeOne Medicines Ltd. Chief Financial Officer Aaron Rosenberg sold 1,157 American Depositary Shares at $312.715 per ADS on August 3, 2026, to satisfy mandatory tax withholding tied to vesting of a restricted share unit award. After this transaction he held 382,850 Ordinary Shares directly. Each American Depositary Share represents 13 Ordinary Shares, and the restricted share unit award vests in four equal annual installments on each anniversary of July 31, 2024, with remaining unvested units eligible for accelerated vesting upon certain termination events.
BeOne Medicines Ltd. reported strong results for the quarter ended June 30, 2026, with total revenues of $1,705,071 (amounts in thousands of $), up 29.6% from $1,315,300 a year earlier. Net income rose to $237,007 from $94,320, and diluted earnings per share were $0.16, or $2.05 per ADS.
Growth was driven mainly by oncology portfolio expansion: BRUKINSA® net product revenue increased 31.4% to $1,247,640, TEVIMBRA® grew 18.1% to $228,515, and Amgen‑in‑licensed products such as XGEVA® and BLINCYTO® also posted double‑digit gains. Overall net product revenue rose 29.0% to $1,679,794, while other revenue nearly doubled to $25,277.
Gross profit improved to $1,530,541, reflecting an 89.6% product gross margin. Research and development expense grew 16.6% to $612,280 and selling, general and administrative expense rose 10.3% to $593,214 as the company invested in its pipeline and global commercialization. Cash and cash equivalents were $5,098,041 at June 30, 2026, alongside $882,163 of long‑term debt, $190,896 of short‑term debt, and a $906,313 sale‑of‑future‑royalty liability.